person
Sara P.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
assignment
7
Clinical Trials ·
- Phase III Trial of BI 764532 Plus Carboplatin and Etoposide Versus Carboplatin and Etoposide in Previously Untreated DLL3-Positive Advanced Extrapulmonary Neuroendocrine Carcinoma
- Phase II Multicenter Single-Arm Study of Durvalumab with Carboplatin or Cisplatin and Etoposide in First-Line Treatment of Extensive Stage Extrapulmonary Small Cell Carcinoma
- Phase II Multicenter Study of Metronomic Temozolomide in Clinically Frail Patients with Advanced Well-Differentiated Neuroendocrine Neoplasms
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
43
Sites with multiple studies
Has run more than one trial at 43 of 134 partner sites.
Specializations
Neuroendocrine Oncology
The investigator specializes in treating neuroendocrine neoplasms (NENs) and neuroendocrine tumors (NETs), with particular focus on both gastroenteropancreatic (GEP) and thoracic manifestations.
- Well-differentiated neuroendocrine tumors
- Advanced disease management
- Clinical frailty considerations
Rare Cancers
Expertise in treating rare malignancies including extrapulmonary small cell carcinoma (EPSCC) and Merkel cell carcinoma, focusing on advanced stages of these conditions.
- Extensive stage carcinomas
- Treatment-naïve advanced cases
- Rare tumor management
Therapeutic Approaches
The investigator explores various therapeutic strategies including immunotherapy combinations and targeted therapies for advanced oncological conditions.
- First-line treatment protocols
- Combined therapy approaches
- Novel therapeutic combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.